Electroencephalographic (EEG) Profils for Patients on Intravenous Ketamine.
WithdrawnNCT05949554
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Chronic pain symptoms can lead to sleep and mood disorders, restrict domestic and work activities and have a significant impact on quality of life. The prevalence of chronic pain in the general population varies between 10 and 52% depending on the study, 7% of which is neuropathic pain. Anxiety-depression comorbidities are found in a large number of patients, with harmful consequences on pain since they exacerbate symptoms and their repercussions. Conversely, pain increases psychological distress. Ketamine has been used in the context of depressive episodes for its rapid action. It is also increasingly used in chronic pain due to its ability to regulate the "wind-up" effect, a phenomenon involved in the central hypersensitization that is inevitably present in neuropathic pain of prolonged duration. Several studies have found electroencephalographic (EEG) signatures associated with a good antidepressant response to Ketamine. The frequency, absolute and relative power and cordance of the EEG signal in certain frequency ranges (theta, alpha, beta and gamma) could be useful to guide and adapt therapies for depression and pain.
Study details
- Official title
- Characterization of Electroencephalographic (EEG) Signatures of Chronic Pain Patients Receiving Intravenous Ketamine.
- Conditions
- Interventions
- Other: Ketamine infusion
- Sponsor
- Assistance Publique - Hôpitaux de Paris
- Collaborators
- INSERM UMR-942, Paris, France; M3DISIM
- Start date
- 2023-09
- Primary completion
- 2024-09
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Total sites listed
- 0
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Patients \> 18 years old * Eligible for Ketamine infusions in the context of chronic pain refractory to usual therapies * Patient informed and having expressed his non-objection to participation in this research * Patient who is not subject to a legal protection measure Exclusion Criteria: * Patients under 18 years of age. * Patients with a contraindication to ketamine. * Patient opposed to protocol participation * Pregnant woman * Patient under legal protection * Patient not affiliated to a social security scheme
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT05949554